Skip to main content
. 2017 Nov 27;8(65):109596–109608. doi: 10.18632/oncotarget.22741

Figure 4. TRIB2 knockdown in Cisplatin-resistant SCLC cells.

Figure 4

(A) TRIB2 mRNA levels in CRSC cells transfected with either TRIB2 siRNA or negative siRNA (**, p < 0.01). (B) TRIB2 protein levels in the CRSC cells transfected with either TRIB2 siRNA or negative siRNA. (C) Immunoblot analysis of apoptotic markers during 48 hrs. Cisplatin-treatment course in the CRSC cells transfected with either TRIB2 siRNA or negative siRNA. (D) Immunoblot analysis of apoptotic marker in CRSC cells treated with Cisplatin and Flavopiridol for 24 hrs.